Ask a chemist what “leaky gut” even means at the molecular level, and you get two very different answers depending on which door you’re pointing at. One answer involves the physical seals between intestinal cells. The other involves the inflammatory signaling that flares up once something gets through those seals anyway. Larazotide and KPV are built for those two different doors, and that distinction, more than any marketing copy, is the entire reason to prefer one over the other for a given problem.
This piece works from primary sources only, PubMed papers and a Celiac Disease Foundation report, all linked at the bottom so nothing here has to be taken on faith. One fact needs to sit up front before anything else: neither peptide is FDA-approved, and neither has a clean, confirmed record of working in actual humans. This is not a comparison between a winner and a runner-up. It’s a comparison between two unproven candidates with very different kinds of unproven-ness. Last updated June 2026.
First, what each molecule was engineered to do
Start with the biology, because it explains everything that follows.
Larazotide, also known as larazotide acetate or AT-1001, is an eight-amino-acid peptide that researchers built by essentially running cholera toxin in reverse. Cholera toxin pries open the tight junctions between gut lining cells; larazotide was designed to help hold those junctions shut. The junctions themselves are gated by a protein called zonulin, and in celiac disease, gluten appears to trigger zonulin to loosen the gate, letting gluten fragments slip across and set off an immune reaction. Larazotide’s job is to blunt that loosening. It stays largely in the gut and isn’t meant to circulate through the body. Mechanically, it’s a barrier peptide, full stop, aimed at the “leaky” half of leaky gut.
KPV works nothing like that. It’s a tripeptide, just three amino acids long (lysine-proline-valine), and it happens to be the tail end of a hormone the body already produces, alpha-melanocyte-stimulating hormone. A 2010 review lays out the curious part: this fragment is missing the piece of the molecule that normally binds the melanocortin receptors, yet it keeps much of the parent hormone’s anti-inflammatory punch anyway, apparently working inside the cell on pathways like NF-kB rather than through the usual receptor route [K2]. So KPV isn’t sealing anything. It’s dialing down inflammatory signaling. Different address, different function entirely.
That’s the whole ballgame, really. Larazotide is about tightness. KPV is about inflammation. Anyone treating these as interchangeable “gut health peptides” is starting from a false premise.
The report card: one peptide sat the human exam, the other hasn’t yet
Here’s a way to think about the evidence gap that’s more useful than a simple “both are unproven” shrug: larazotide has actually turned in its homework, in the form of real human trials, and the grades came back disappointing. KPV hasn’t taken the human exam at all yet; it’s still doing preclinical coursework in cells and mice.
Larazotide’s early permeability studies missed their primary endpoints. Then came a genuinely encouraging result: a 2015 trial in 342 celiac patients with lingering symptoms despite a gluten-free diet hit its primary endpoint, but only at the lowest dose tested, 0.5 mg; the higher doses did nothing extra [K1]. That’s the kind of dose-response inversion that makes a pharmacologist raise an eyebrow. The follow-up, the first-ever Phase 3 trial in celiac disease, was halted in June 2022 for futility, meaning interim data showed it wasn’t on pace to demonstrate a benefit [K3]. Pooling four trials and 626 patients, a meta-analysis concluded larazotide was modestly better than placebo on symptoms during a gluten challenge, but unlikely to be a definitive treatment [K4]. So larazotide’s transcript is long and mostly underwhelming: real trials, a clever mechanism, and a benefit that never quite confirmed itself.
KPV’s transcript looks almost like a mirror image. The foundational 2008 paper found that KPV gets ferried into intestinal and immune cells by a transporter called PepT1, where it damped down inflammatory signaling, and that oral KPV reduced the severity of chemically induced colitis in mice [K5]. A second 2008 study found similar anti-inflammatory effects across more mouse colitis models, and notably the peptide still worked in mice engineered to lack a functioning melanocortin-1 receptor, which supports the idea that it isn’t working through the classic receptor pathway. Those researchers said outright that clinical trials would be needed to confirm the effect in people [K6]. That caveat hasn’t been resolved. As of 2026, there is no adequately powered, randomized, controlled human trial showing KPV does anything for any condition in people, and it carries no FDA approval.
Line the two records up and the asymmetry is stark. Larazotide has human data, and most of it is discouraging. KPV has an interesting, biologically coherent story, and almost no human data whatsoever. Neither gets you the thing you actually want, a peptide with confirmed human benefit for your specific problem.
Matching the molecule to the actual complaint
The practical question isn’t “which peptide is better,” it’s “which peptide was even aimed at my problem.”
If the concern is barrier permeability itself, particularly anything tied to gluten and celiac disease, larazotide is the molecule that was designed and tested for exactly that job. The uncomfortable footnote is that even on its home turf, the evidence disappointed and the Phase 3 trial failed for futility. So “the right tool” here still comes with “the tool that was tried and largely came up short” attached. That’s not an endorsement, just an honest statement of relevance.
If the concern is gut inflammation more broadly, KPV is the molecule whose mechanism actually points that direction, and its preclinical colitis results are the reason it keeps coming up in that conversation [K5][K6]. The size of the caveat matches the size of the promise: everything supporting that case comes from cells and mice, not people.
If the goal is something vaguer, a general sense that “gut health” needs fixing without a specific target, neither peptide has earned that purchase. Larazotide was tested for celiac permeability and didn’t confirm a benefit. KPV was tested for inflammation in animals and has essentially never been tested in people. A fuzzy goal like “gut health” is precisely the kind of target that’s easy to sell against and hard to disprove, because nothing specific was ever promised. The more useful move, if that’s the situation, is getting an actual diagnosis before reaching for either peptide.
The shared problem underneath both of them
However the goal is defined, both peptides run into the same structural issue: neither is FDA-approved, and both circulate heavily as “research chemicals,” sold in vials stamped “for research use only, not for human consumption.” That label isn’t boilerplate. It’s the seller stating, in writing, that the product was never screened or intended to go into a human body, and that whatever happens after that is not their problem. Buying that way means no clinician reviewed your history, no pharmacy verified what’s actually in the vial, and no one is accountable if the contents don’t match the label. For larazotide, that means self-dosing a compound whose own pivotal trial failed to clear the bar. For KPV, it means self-dosing something with almost no human safety or efficacy data at all.
The fix for that specific problem doesn’t depend on which peptide someone ends up choosing: put a licensed clinician and a licensed pharmacy in the middle of the transaction. Under that kind of supervised arrangement, an independent clinician reviews the history, writes a prescription where it’s warranted, and a licensed compounding pharmacy actually prepares and ships the product, with follow-up built in. FormBlends operates on that model, delivering both larazotide and KPV as compounded prescriptions rather than unlabeled research powder. Routing the purchase this way doesn’t turn either molecule into a proven one. A trustworthy provider will say plainly that larazotide’s trials underdelivered and that KPV’s human record barely exists. What supervision buys is screening, a label that matches what’s actually inside, and a real person weighing two unproven options against an actual medical situation, rather than a shopping cart doing it.
The science itself doesn’t move. Adding a clinician changes who’s accountable for what happens next, not what the studies actually found.
Where that leaves the decision
If a choice between larazotide and KPV is unavoidable, let the target decide, not the marketing. Larazotide is the barrier-tightening peptide with a real but mostly disappointing human trial record, most relevant for gluten-linked permeability concerns. KPV is the anti-inflammatory peptide with encouraging animal data and almost no human data, most relevant for gut inflammation. Neither is proven in people. Neither is FDA-approved. Both circulate as research chemicals stripped of ordinary safety checks. The peptide chosen matters less than the path it arrives by. Pick the one whose mechanism fits the actual problem, hold no illusions about how thin the human evidence is for either, and if moving forward at all, do it through a clinician and a pharmacy rather than a cart and a guess.
Questions worth answering
Is larazotide or KPV better for leaky gut?
It depends which half of “leaky gut” is meant. Larazotide is the only one of the two built and tested to physically tighten the intestinal barrier, so for true permeability concerns, especially anything gluten-linked, it’s the more relevant molecule even though its trials underperformed [1]. KPV doesn’t touch the barrier itself; it works on inflammation. Barrier concerns point toward larazotide; inflammation-driven symptoms point toward KPV.
Does KPV have any human trials behind it?
No. As of 2026 there’s no adequately powered, randomized, controlled human trial demonstrating KPV treats any condition in people, and it holds no FDA approval [5][6]. Everything supporting it comes from cell and mouse work, where it reduced inflammatory signaling and eased chemically induced colitis. The scientists behind that animal research said explicitly that human trials would still be needed to confirm any of it.
Why did larazotide’s Phase 3 trial fail?
The Phase 3 CeDLara trial was halted in June 2022 for futility, meaning an interim look at the data showed it wasn’t on track to beat placebo [3]. That followed a pattern already visible in earlier work: initial permeability studies missed their primary endpoints, and the one promising 2015 result only held at the lowest 0.5 mg dose, with higher doses adding nothing [1]. A meta-analysis pooling four trials called the overall effect modestly better than placebo, unlikely to amount to a cure [4].
Can larazotide and KPV be combined?
There’s no human evidence for either peptide alone, so combining them is speculation without data to back it. They do target different systems, barrier integrity versus inflammation, so pairing them makes mechanistic sense on paper. Mechanistic sense on paper isn’t the same as tested in a trial, though, and no controlled study has looked at the combination.
Are these peptides legal to buy?
They’re widely sold as research chemicals labeled “for research use only” or “not for human consumption,” language that signals the product was never screened or meant for human use. Neither is an approved drug available at a standard pharmacy. The supervised alternative is obtaining either one as a compounded prescription through a licensed clinician and a licensed compounding pharmacy, the route the FormBlends model follows.
Which one should be picked for general gut health?
Neither, if “general gut health” is the entire goal. Larazotide was tested for celiac permeability and didn’t confirm a benefit; KPV was tested for inflammation in animals and hasn’t been seriously tested in humans. A loose target like this is exactly what unproven products get marketed against, since nothing specific has to be shown. The more useful step is getting an actual diagnosis before choosing a peptide to aim at it.
References
- Leffler DA, et al. Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. Gastroenterology, 2015;148(7):1311-1319. (n=342); primary endpoint met at the 0.5 mg dose only; higher doses did not separate from placebo. https://pubmed.ncbi.nlm.nih.gov/25683116/
- Brzoska T, et al. Terminal signal: anti-inflammatory effects of alpha-melanocyte-stimulating hormone related peptides beyond the pharmacophore. Advances in Experimental Medicine and Biology, 2010 (review). The C-terminal KPV fragment lacks the melanocortin-receptor binding motif yet retains much of alpha-MSH’s anti-inflammatory activity, acting on pathways including NF-kB. https://pubmed.ncbi.nlm.nih.gov/21222263/
- Celiac Disease Foundation. 9 Meters discontinues Phase 3 clinical trial for potential celiac disease drug larazotide. 2022. Phase 3 CeDLara stopped in June 2022 for futility; larazotide not FDA-approved.
- Hoilat GJ, et al. Larazotide acetate for treatment of celiac disease: a systematic review and meta-analysis of randomized controlled trials. Clinical Research in Hepatology and Gastroenterology, 2022;46(1). Four RCTs, 626 patients; modestly better than placebo on GI symptoms during gluten challenge, less likely to offer a definitive cure.
- Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology, 2008. KPV enters intestinal and immune cells via PepT1, inhibits NF-kB and MAP-kinase signaling at nanomolar levels, and reduces DSS- and TNBS-induced colitis in mice.
- Kannengiesser K, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases, 2008;14(3):324-331. KPV reduced inflammation in mouse colitis models and worked in MC1R-deficient mice; authors note human trials are still needed.
So what does larazotide actually do inside the gut?
Mechanistically, it interrupts zonulin signaling at the tight junctions, the molecular gates between intestinal cells that decide what’s allowed to cross into the bloodstream. Keep those gates shut and the immune system encounters fewer stray food proteins and bacterial fragments. In celiac research, that translated into measurable drops in permeability markers. It doesn’t repair villi already damaged by disease, and it’s not a substitute for a gluten-free diet. It targets the gate mechanism specifically, nothing more.
How safe does larazotide look based on the trials run so far?
Across the Phase 2 celiac trials, the safety profile looked reasonably clean. The most common complaints were mild GI symptoms, nausea or abdominal discomfort, at rates not dramatically above placebo. No serious organ-toxicity signal turned up. That said, those trials ran weeks to months, not years, so anything about longer-term safety simply isn’t known yet. Anyone weighing it outside a supervised trial setting should treat that gap honestly rather than assume the absence of long-term data means the absence of long-term risk.
What dose of larazotide did the trials actually use?
The dose that performed best in celiac trials was 0.5 mg, taken three times daily, a result researchers themselves found somewhat counterintuitive since higher doses up to 4 mg three times daily didn’t add benefit despite an acceptable safety profile. There’s no validated dosing framework for any use outside celiac disease, so applying these numbers to other goals is guesswork, not established science.
Where would someone actually get larazotide, and what should they watch for?
It isn’t FDA-approved or sold at a standard US pharmacy. Research-chemical sellers offer it as raw peptide with no oversight, inconsistent purity, and zero accountability if something’s wrong with the vial. A more accountable route runs through a physician-supervised compounding pharmacy, such as FormBlends, where a licensed prescriber is actually involved and sourcing is documented. Without that layer, there’s really no way to confirm what’s in the bottle at all.
Isaac Moreno is a science reporter who writes about the biology behind emerging compounds and the evidence gaps that separate mechanism from proof.
Not medical advice. Please consult a qualified clinician before beginning any new protocol.
